Physician profile
Thomas Edwards
NPI 1326029125
$6,720.74
in general payments reported to CMS, 2019-2025
23 companies · $464 in 2025
The $464 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,225 · 2020: $660 · 2021: $1,022 · 2022: $1,211 · 2023: $1,038 · 2024: $101 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,896.49 | 2019-2023 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Allergan, INC. | $837.91 | 2019-2022 | |
| Alcon Vision LLC | $743.55 | 2019-2025 | Ngenuity, Clareon Panoptix Pro, Tryptyr |
| Sun Pharmaceutical Industries INC. | $635.57 | 2019-2024 | Cequa |
| Abbvie INC. | $312.45 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Aerie Pharmaceuticals, INC. | $290.54 | 2019-2021 | |
| Glaukos Corporation | $239.71 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $229.35 | 2021-2023 | Acthar |
| Oyster Point Pharma, INC. | $228.10 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $201.88 | 2019-2021 | |
| Medtronic, INC. | $190.91 | 2025 | Stealthstation S8 Platform |
| Harrow Eye, LLC | $174.84 | 2023-2025 | Iheezo, Vevye |
| Rxsight INC | $130.68 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.83 | 2019-2021 | |
| Amgen INC. | $102.18 | 2024-2025 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $99.18 | 2019-2022 | |
| Sight Sciences, INC. | $75.63 | 2022-2023 | Tearcare System |
| Bausch & Lomb Americas INC. | $71.15 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Shire North American Group INC | $49.97 | 2019 | |
| Glaxosmithkline, LLC. | $43.20 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $26.00 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $15.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.